Highest-materiality recent filing
Offering of 42,688,606 shares (or pre-funded warrants) plus two-year and five-year milestone warrants at combined price of $0.3221 per share.
AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%
FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit
March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.
AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%
Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.
AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares
John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.
AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA
Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.
AEON Biopharma reports positive ABP-450 biosimilarity data, secures $6M PIPE and debt reduction
ABP-450 shows 100% amino-acid sequence identity to BOTOX (93-99% coverage across five proteins) and highly similar functional characteristics.
AEON Biopharma raises $6M private placement, plans Daewoong note exchange for ~23M shares
First closing of private placement expected week of Nov 17, 2025: 1,964,905 shares/pre-funded warrants at $0.9116 per share.
AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones
Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.
AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash
Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.
NYSE American accepts AEON's compliance plan; delisting risk deferred to Aug 2026
NYSE American accepted AEON's compliance plan on April 22, 2025, granting until August 3, 2026 to meet listing standards under Sections 1003(a)(i)-(iii).
AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman
Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.
AEON CEO Marc Forth resigns; Chairman Jost Fischer named interim CEO
Marc Forth steps down as President and CEO effective April 4, 2025, to pursue another opportunity.
AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding
Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.
AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing
Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.
AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M
Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
AEON Biopharma closes $20M public offering; net proceeds ~$18.3M
Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).
AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025
Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.
AEON Biopharma Q3 2024: FDA aligned on biosimilar path for ABP-450, but capital constraints persist
Held Biosimilar Initial Advisory meeting with FDA in Q3; aligned on 351(k) pathway using BOTOX as reference.
AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024
ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.
ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.
Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.
AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints
Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.
AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint
Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.
AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt
Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.
AEON Biopharma issues $10M convertible note to Daewoong, appoints Daewoong CEO to board
Issued $10M senior secured convertible note to Daewoong on April 12, 2024, with 15.79% annual interest and maturity April 12, 2027.
AEON Biopharma reports FY 2023 results; aligns with FDA on Phase 3 migraine design
End-of-Phase 2 meeting with FDA achieved alignment on pivotal Phase 3 trial design for episodic and chronic migraine.
AEON Biopharma closes $5M secured convertible note with Daewoong; 15.79% interest
Issued $5M senior secured convertible note to Daewoong Pharmaceutical as initial closing of $15M subscription agreement.
Issues up to $15M senior secured convertible notes to Daewoong; first $5M tranche closes within 10 days, second $10M subject to license amendment.
Audit Committee concludes Sep 30, 2023 financials unreliable due to valuation errors in contingent consideration, convertible notes, stock comp, and derivatives.
AEON Biopharma Q3 cash $16.2M; Phase 2 episodic migraine misses primary endpoint
Cash, equivalents and investments $16.2M as of Sep 30, 2023; expects to fund operations only into mid-December 2023.
Primary endpoint not met: mean MMD reduction of 4.8 days (150U) and 5.0 days (195U) vs 4.2 days placebo; p-values not significant (0.2844, 0.1711).
AEON Biopharma reports H1 2023 net loss of $33M; cash at $2.6M with going-concern doubt
Net loss of $33.0M for six months ended June 30, 2023 vs $7.6M loss in H1 2022.
Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.
On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.
On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.
On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.
The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.
On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.
On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.
On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.
On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.
the Board of Directors (the “Board”) of the Company appointed Seongsoo Park as a Class III director of the Board, effective as of April 12, 2024.
Max materiality 0.90 · Median 0.62 · Most common event other_material